<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38601488</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Exploring the path to polio eradication: insights from consecutive seroprevalence surveys among Pakistani children.</ArticleTitle><Pagination><StartPage>1384410</StartPage><MedlinePgn>1384410</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1384410</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1384410</ELocationID><Abstract><AbstractText Label="INTRODUCTION">After trivalent oral poliovirus vaccine (tOPV) cessation, Pakistan has maintained immunity to type 2 poliovirus by administering inactivated polio vaccine (IPV) in routine immunization, alongside monovalent OPV type 2 (mOPV2) and IPV in supplementary immunization activities (SIAs). This study assesses the change in poliovirus type 2 immunity after tOPV withdrawal and due to SIAs with mOPV2 and IPV among children aged 6-11 months.</AbstractText><AbstractText Label="METHODS">Three cross-sectional sequential serological surveys were conducted in 12 polio high-risk areas of Pakistan. 25 clusters from each geographical stratum were selected utilizing probability proportional to size.</AbstractText><AbstractText Label="RESULTS">Seroprevalence of type 2 poliovirus was 49%, with significant variation observed among surveyed areas; &lt;30% in Pishin, &gt;80% in Killa Abdullah, Mardan &amp; Swabi, and Rawalpindi. SIAs with IPV improved immunity from 38 to 57% in Karachi and 60 to 88% in Khyber. SIAs with IPV following mOPV2 improved immunity from 62 to 65% in Killa Abdullah, and combined mOPV2 and IPV SIAs in Pishin improved immunity from 28 to 89%. Results also reflected that immunity rates for serotypes 1 and 3 were consistently above 90% during all three phases and across all geographical areas.</AbstractText><AbstractText Label="CONCLUSION">The study findings highlight the importance of implementing effective vaccination strategies to prevent the re-emergence of poliovirus. Moreover, the results provide crucial information for policymakers working toward achieving global polio eradication.</AbstractText><CopyrightInformation>Copyright © 2024 Hussain, Umer, Khan, Sajid, Ahmed, Begum, Iqbal, Alam, Safdar, Baig, Voorman, Partridge and Soofi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hussain</LastName><ForeName>Imtiaz</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center of Excellence in Women and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Umer</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of Excellence in Women and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Khan</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center of Excellence in Women and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajid</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of Excellence in Women and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Imran</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center of Excellence in Women and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Begum</LastName><ForeName>Kehkashan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Junaid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Muhammad M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>National Institute of Health (Pakistan), Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safdar</LastName><ForeName>Rana M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Polio National Emergency Operations Center, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baig</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Polio National Emergency Operations Center, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voorman</LastName><ForeName>Arie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bill and Melinda Gates Foundation, Seattle, WA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partridge</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bill and Melinda Gates Foundation, Seattle, WA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soofi</LastName><ForeName>Sajid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Excellence in Women and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, The Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010154" MajorTopicYN="N" Type="Geographic">Pakistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pakistan</Keyword><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword><Keyword MajorTopicYN="N">type 2 immunity</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38601488</ArticleId><ArticleId IdType="pmc">PMC11004230</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1384410</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moffett DB, Llewellyn A, Singh H, Saxentoff E, Partridge J, Boualam L, et al. . Progress toward poliovirus containment implementation – worldwide, 2019–2020. MMWR Morb Mortal Wkly Rep. (2020) 69:1330–3. doi: 10.15585/mmwr.mm6937a7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6937a7</ArticleId><ArticleId IdType="pmc">PMC7498175</ArticleId><ArticleId IdType="pubmed">32941411</ArticleId></ArticleIdList></Reference><Reference><Citation>Chard AN, Datta D, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF, et al. . Progress toward polio eradication — worldwide, January 2018–march 2020. MMWR. (2020) 69:784–9. doi: 10.15585/mmwr.mm6925a4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6925a4</ArticleId><ArticleId IdType="pmc">PMC7316320</ArticleId><ArticleId IdType="pubmed">32584798</ArticleId></ArticleIdList></Reference><Reference><Citation>Haqqi A, Zahoor S, Aftab MN, Tipu I, Rehman Y, Ahmed H, et al. . COVID-19 in Pakistan: impact on global polio eradication initiative. J Med Virol. (2020) 93:141–3. doi: 10.1002/jmv.26240, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26240</ArticleId><ArticleId IdType="pmc">PMC7361542</ArticleId><ArticleId IdType="pubmed">32603503</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakistan Polio Eradication Programme . (2023). Polio cases in provinces. Available at: https://www.endpolio.com.pk/polioin-pakistan/polio-cases-in-provinces</Citation></Reference><Reference><Citation>Din M, Ali H, Khan M, Waris A, Ullah S, Kashif M, et al. . Impact of COVID-19 on polio vaccination in Pakistan: a concise overview. Rev Med Virol. (2021) 31:e2190. doi: 10.1002/rmv.2190, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2190</ArticleId><ArticleId IdType="pubmed">33176028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Khan A, Rhoda DA, Ahmed I, Umer M, Ansari U, et al. . Routine immunization coverage and immunization card retention in Pakistan: results from a cross-sectional National Survey. Pediatr Infect Dis J. (2023) 42:260–70. doi: 10.1097/INF.0000000000003804, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003804</ArticleId><ArticleId IdType="pmc">PMC9935567</ArticleId><ArticleId IdType="pubmed">36728580</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. (2014) 210:S380–9. doi: 10.1093/infdis/jiu184, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu184</ArticleId><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, et al. . Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. (2020) 5:26. doi: 10.1038/s41541-020-0176-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0176-7</ArticleId><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, Habib MA, Hussian I, Safdar RM, Ahmed JA, Weldon WC, et al. . Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: a population-based serological study in Pakistan. Vaccine. (2020) 5:100067. doi: 10.1016/j.jvacx.2020.100067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2020.100067</ArticleId><ArticleId IdType="pmc">PMC7240192</ArticleId><ArticleId IdType="pubmed">32462141</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. (2015) 10:791–808. doi: 10.2217/fmb.15.19, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.19</ArticleId><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Molodecky NA, O'Reilly KM, Wadood MZ, Safdar RM, Etsano A, et al. . Population immunity against Serotype-2 poliomyelitis leading up to the global withdrawal of the Oral poliovirus vaccine: Spatio-temporal modelling of surveillance data. PLoS Med. (2016) 13:e1002140. doi: 10.1371/journal.pmed.1002140, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002140</ArticleId><ArticleId IdType="pmc">PMC5049753</ArticleId><ArticleId IdType="pubmed">27701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon J, Seib K, Orenstein WA, Gonzalez AR, Blanc DC, Zaffran M, et al. . Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. (2016) 15:693–708. doi: 10.1586/14760584.2016.1140041, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1140041</ArticleId><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI . (2016) Global synchronisation and the switch. Available at: https://polioeradication.org/news-post/global-synchronisation-and-the-switch/#:~:text=What%20is%20the%20switch%3F,of%20another%20vaccine%20in%20history (Accessed March 27, 2023).</Citation></Reference><Reference><Citation>Taniuchi M, Famulare M, Zaman K, Uddin MJ, Upfill-Brown AM, Ahmed T, et al. . Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study. Lancet Infect Dis. (2017) 17:1069–79. doi: 10.1016/S1473-3099(17)30358-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30358-4</ArticleId><ArticleId IdType="pmc">PMC5610141</ArticleId><ArticleId IdType="pubmed">28693854</ArticleId></ArticleIdList></Reference><Reference><Citation>Concepción FE, Mark AP, Abhijeet A, Steven GFW, Roland WS, Jay DW, et al. . Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. (2013) 3:309–15. doi: 10.1016/j.coviro.2013.05.007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2013.05.007</ArticleId><ArticleId IdType="pmc">PMC10395005</ArticleId><ArticleId IdType="pubmed">23759252</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare M, Selinger C, McCarthy KA, Eckhoff PA, Chabot-Couture G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. PLoS Biol. (2018) 16:e2002468. doi: 10.1371/journal.pbio.2002468, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.2002468</ArticleId><ArticleId IdType="pmc">PMC5942853</ArticleId><ArticleId IdType="pubmed">29702638</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamougam K, Jeyaseelan V, Jones KAV, Mainou BA, Palmer T, Diaha A, et al. . A survey to assess serological prevalence of poliovirus antibodies in areas with high-risk for vaccine-derived poliovirus transmission in Chad. J Pediatric Infect Dis Soc. (2022) 11:55–9. doi: 10.1093/jpids/piab103, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piab103</ArticleId><ArticleId IdType="pmc">PMC8865003</ArticleId><ArticleId IdType="pubmed">34791366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by Oral and inactivated poliovirus vaccines against virus shedding following Oral poliovirus challenge. PLoS Pathog. (2012) 8:e1002599. doi: 10.1371/journal.ppat.1002599, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002599</ArticleId><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA, Diop OM, Iber J, Tallis G, et al. . Update on vaccine-derived poliovirus outbreaks – worldwide, July 2019 – February 2020. MMWR. (2020) 69:489–95. doi: 10.15585/mmwr.mm6916a1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6916a1</ArticleId><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, MA P. Standardized methods for detection of poliovirus antibodies. New York: Springer; (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. (2010) 17:1055–65. doi: 10.1128/CVI.00131-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00131-10</ArticleId><ArticleId IdType="pmc">PMC2897268</ArticleId><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreevatsava M, Burman AL, Wahdan A, Safdar RM, O'Leary A, Amjad R, et al. . Routine immunization coverage in Pakistan: a survey of children under 1 year of age in community-based vaccination areas. Vaccine. (2020) 38:4399–404. doi: 10.1016/j.vaccine.2020.04.068, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.04.068</ArticleId><ArticleId IdType="pubmed">32402754</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RC . R: A language and environment for statistical computing. Vienna: Foundation for Statistical Computing; (2015).</Citation></Reference><Reference><Citation>Hussain I, Mach O, Habib A, Bhatti Z, Suhag Z, Oberste MS, et al. . Seroprevalence of anti-polio antibodies in children from polio high-risk areas of Pakistan: a cross-sectional survey 2015-2016. Pediatr Infect Dis J. (2017) 36:e230–6. doi: 10.1097/INF.0000000000001622, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001622</ArticleId><ArticleId IdType="pmc">PMC9131303</ArticleId><ArticleId IdType="pubmed">28806355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Mach O, Hamid NA, Bhatti ZS, Moore DD, Oberste MS, et al. . Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: a cross sectional survey 2017. Vaccine. (2018) 36:1921–4. doi: 10.1016/j.vaccine.2018.02.055, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.055</ArticleId><ArticleId IdType="pmc">PMC5873527</ArticleId><ArticleId IdType="pubmed">29510918</ArticleId></ArticleIdList></Reference><Reference><Citation>Soofi SB, Martinez M, Farag NH, Hendley WS, Ehrhardt D, Ahmed I, et al. . Poliovirus immunity among children aged 6–11 and 36–48 months in 14 polio high-risk provinces of Afghanistan: a Health-facility-based study. Vaccine. (2022) 10:1726. doi: 10.3390/vaccines10101726, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101726</ArticleId><ArticleId IdType="pmc">PMC9610936</ArticleId><ArticleId IdType="pubmed">36298591</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande JM, Bahl S, Sarkar BK, Estívariz CF, Sharma S, Wolff C, et al. . Assessing population immunity in a persistently high-risk area for wild poliovirus transmission in India: a serological study in Moradabad, Western Uttar Pradesh. J Infect Dis. (2014) 210 Suppl 1:S225–33. doi: 10.1093/infdis/jiu204, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu204</ArticleId><ArticleId IdType="pmc">PMC10325558</ArticleId><ArticleId IdType="pubmed">25316839</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, Hoff NA, Doshi RH, Alfonso V, Mukadi P, Muyembe-Tamfum JJ, et al. . Polio immunity and the impact of mass immunization campaigns in the Democratic Republic of the Congo. Vaccine. (2017) 35:5693–9. doi: 10.1016/j.vaccine.2017.08.063, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.08.063</ArticleId><ArticleId IdType="pmc">PMC5628608</ArticleId><ArticleId IdType="pubmed">28882442</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>